- Home
- WPP vs VTRS Comparison
WPP vs VTRS Comparison
Compare WPP & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WPP
- VTRS
- Stock Information
- Founded
- WPP 1985
- VTRS 1961
- Country
- WPP United Kingdom
- VTRS United States
- Employees
- WPP N/A
- VTRS N/A
- Industry
- WPP Advertising
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- WPP Consumer Discretionary
- VTRS Health Care
- Exchange
- WPP Nasdaq
- VTRS Nasdaq
- Market Cap
- WPP 7.6B
- VTRS 9.0B
- IPO Year
- WPP N/A
- VTRS N/A
- Fundamental
- Price
- WPP $38.88
- VTRS $9.09
- Analyst Decision
- WPP Hold
- VTRS Hold
- Analyst Count
- WPP 1
- VTRS 4
- Target Price
- WPP N/A
- VTRS $10.50
- AVG Volume (30 Days)
- WPP 317.1K
- VTRS 13.5M
- Earning Date
- WPP 02-27-2025
- VTRS 05-08-2025
- Dividend Yield
- WPP 3.06%
- VTRS 5.28%
- EPS Growth
- WPP 389.11
- VTRS N/A
- EPS
- WPP 0.62
- VTRS N/A
- Revenue
- WPP $18,454,623,978.00
- VTRS $14,330,200,000.00
- Revenue This Year
- WPP N/A
- VTRS N/A
- Revenue Next Year
- WPP $1.94
- VTRS $1.20
- P/E Ratio
- WPP $12.23
- VTRS N/A
- Revenue Growth
- WPP N/A
- VTRS N/A
- 52 Week Low
- WPP $31.52
- VTRS $6.85
- 52 Week High
- WPP $57.37
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- WPP 56.22
- VTRS 65.82
- Support Level
- WPP $38.46
- VTRS $8.47
- Resistance Level
- WPP $39.46
- VTRS $8.76
- Average True Range (ATR)
- WPP 0.56
- VTRS 0.27
- MACD
- WPP 0.42
- VTRS 0.17
- Stochastic Oscillator
- WPP 87.45
- VTRS 76.96
About WPP WPP plc
Headquartered in the United Kingdom, WPP is one of the world's largest ad holding companies based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.